Maximum quantity allowed is 999
Please select the quantity
CAS RN: 103060-53-3 | Product Number: D4229
Daptomycin
Purity: >94.0%(HPLC)(N)
Synonyms:
Product Documents:
Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time | Shipping Information |
---|---|---|---|---|---|
100MG |
$119.00
|
13 | ≥40 | Contact Us |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
Product Number | D4229 |
Purity / Analysis Method | >94.0%(HPLC)(N) |
Molecular Formula / Molecular Weight | C__7__2H__1__0__1N__1__7O__2__6 = 1,620.69 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Frozen (-20°C) |
Condition to Avoid | Heat Sensitive |
Packaging and Container | 100MG-Glass Bottle with Plastic Insert (View image) |
CAS RN | 103060-53-3 |
Reaxys Registry Number | 8186242 |
PubChem Substance ID | 172089104 |
Merck Index (14) | 2823 |
MDL Number | MFCD08282794 |
Specifications
Appearance | White to Yellow to Orange powder to crystal |
Purity(HPLC) | min. 94.0 area% |
Purity(with Total Nitrogen) | min. 94.0 % |
NMR | confirm to structure |
Properties (reference)
Maximum Absorption Wavelength | 260(EtOH) nm |
Solubility (soluble in) | Methanol |
GHS
Related Laws:
RTECS# | HB5626000 |
Transport Information:
H.S.code* | 2941.90-000 |
Application
Studies on the Antibiotic Activity of Daptomycin
References
- Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus
- In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains
- Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus
- Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus
- Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections
- Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.